Updated: Off-the-shelf cell therapy pioneer Allogene recruits a Kite vet to run R&D
After riding out much of a rough year at Instil Bio — capped by a decision to pause and then scrap the lead tumor-infiltrating lymphocyte program and slash more than half the staff — Zachary Roberts will be ringing in the new year as the head of R&D at one of the pioneers of off-the-shelf cell therapies.
Allogene chief David Chang offered me a preview of the switch, which sees Rafael Amado making his exit from Allogene in an anticipated change to a new — and so far still unrevealed — post in biotech.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.